Visakorpi T - Search Results

1

Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS. Högnäs G, et al. Among authors: visakorpi t. Am J Surg Pathol. 2018 Jan;42(1):103-115. doi: 10.1097/PAS.0000000000000961. Am J Surg Pathol. 2018. PMID: 28984675

2

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Am J Pathol. 1995 Dec;147(6):1608-14. Am J Pathol. 1995. PMID: 7495286 Free PMC article.

3

Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.

Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Visakorpi T, et al. Cancer Res. 1995 Jan 15;55(2):342-7. Cancer Res. 1995. PMID: 7529134

4

Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.

Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP. Visakorpi T, et al. Am J Pathol. 1994 Sep;145(3):624-30. Am J Pathol. 1994. PMID: 8080044 Free PMC article.

5

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

6

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

7

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: visakorpi t. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

8

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T. Linja MJ, et al. Among authors: visakorpi t. Cancer Res. 2001 May 1;61(9):3550-5. Cancer Res. 2001. PMID: 11325816

9

Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T. Isola J, et al. Among authors: visakorpi t. J Urol. 2001 May;165(5):1569-74. J Urol. 2001. PMID: 11342919 Clinical Trial.

10

Amplification of urokinase gene in prostate cancer.

Helenius MA, Saramäki OR, Linja MJ, Tammela TL, Visakorpi T. Helenius MA, et al. Among authors: visakorpi t. Cancer Res. 2001 Jul 15;61(14):5340-4. Cancer Res. 2001. PMID: 11454671

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters